• Molecular NameEtoricoxib
  • Synonymetoricoxib; MK-663
  • Weight358.849
  • Drugbank_IDDB01628
  • ACS_NO202409-33-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.21
  • pkaN/A
  • LogD (pH=7, predicted)3.21
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.7
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.07
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds3
  • TPSA68.3
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1) from Merck & Co. Doses are 60, 90 mg/day for chronic pain and 120 mg/day for acute pain.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding92.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, CYP extensively involved (mainly CYP3A4)
  • Half life22 h
  • ExcretionRenal (70%) and fecal (20%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThis reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo
  • LD50 (rat)N/A
  • LD50 (mouse)N/A